US equities |
MU $981.43 ▼-4.62% SNDK $1,470.19 ▼-7.06% NVDA $225.32 ▼-1.73% SPCX $163.40 ▲+0.51% META $743.22 ▲+3.42% AMD $589.59 ▼-3.04% AAPL $341.36 ▲+1.40% INTC $101.10 ▼-3.44%
FinancialContent

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

251.60 -8.26 (-3.18%)
Delayed Quote Updated: 10:24 AM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Expert Ratings For Praxis Precision Medicine ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine ↗
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Praxis Precision Medicine ↗
 
Via Benzinga
News headline image
Demystifying Praxis Precision Medicine: Insights From 7 Analyst Reviews ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug ↗
Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction... 
Via Benzinga
News headline image
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results ↗
 
Via Benzinga
News headline image
PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Misses Revenue for Q2 2024 ↗
PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Are We Having Fun Yet? Stocks Sell Off On Massive Volume ↗
In this video, I review the overall market, my game-plan with the indices, how our largest swings are holding up, and the stocks on my radar. 
Via Talk Markets
News headline image
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails ↗
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
News headline image
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Quarterly & Long-Term Portfolios For The Win ↗
What a day for Meta! I was planning to add to my position, but the volume was too low. I would have been shaken out of most of it for the swing before it could become this position trade. 
Via Talk Markets
News headline image
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst ↗
Needham rates Praxis Precision Medicines Buy with a $145 target. Key programs include ulixacaltamide for essential tremor (Phase 3 results expected in 2024) and PRAX-628 for focal seizures. 
Via Benzinga
News headline image
Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure ↗
The companies are working on treatments for essential tremor, a tricky indication. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >